✦ LIBER ✦

Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma

✍ Scribed by Albert Y. Lin; Nathalie Brophy; George A. Fisher; Sam So; Christopher Biggs; Torunn I. Yock; Lee Levitt

Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 86 KB
Volume: 103
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.20732

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 study of erlotinib in patients w

Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

✍ Melanie B. Thomas; Romil Chadha; Katrina Glover; Xuemei Wang; Jeffrey Morris; Th 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 1 views

## Abstract ## BACKGROUND. Growth factor overexpression, including epidermal growth factor receptor (EGFR) expression, is common in hepatocellular cancers. Erlotinib is a receptor tyrosine kinase inhibitor with specificity for EGFR. The primary objective of this study was to determine the proporti

Thalidomide in the treatment of patients

Thalidomide in the treatment of patients with hepatocellular carcinoma : A Phase II trial

✍ Yehuda Z. Patt; Manal M. Hassan; Richard D. Lozano; Ajay K. Nooka; Isaac I. Schn 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 1 views

## Abstract ## BACKGROUND The treatment of patients with hepatocellular carcinoma (HCC) presents a major challenge, because associated cirrhosis limits the choice of chemotherapeutic agents. However, the abundant vascularity of HCC presents an attractive target for antiangiogenic therapy that pote

Phase II study of gemcitabine in patient

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma

✍ Tai-Shen Yang; Yung-Chang Lin; Jen-Shi Chen; Hung-Ming Wang; Chen-Hsu Wang 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 3 views

A Phase II study of irinotecan in patien

A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma

✍ Eileen M. O'Reilly; Keith E. Stuart; Pedro M. Sanz-Altamira; Gary K. Schwartz; C 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB 👁 2 views

Evaluation of responses to chemoemboliza

Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma

✍ Osama M. Ebied; Michael P. Federle; Brian I. Carr; Karen M. Pealer; Wei Li; Nikh 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 280 KB 👁 1 views

## Abstract ## BACKGROUND The authors used computed tomography (CT) scans to correlate the changes in tumor vascularity, necrosis, and size with response and survival after transcatheter arterial chemoembolization (TACE) in patients with advanced, unresectable, hepatocellular carcinoma (HCC). ##

Phase 2 study of cetuximab in patients w

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

✍ Andrew X. Zhu; Keith Stuart; Lawrence S. Blaszkowsky; Alona Muzikansky; Donald P 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB

## Abstract ## BACKGROUND. Epidermal growth factor receptor (EGFR) and ligand expression is frequently seen in hepatocellular carcinoma (HCC). A phase 2 study was performed with cetuximab, a chimeric monoclonal antibody that binds specifically to EGFR, in patients with advanced HCC. ## METHODS.